Aardvark Therapeutics
Aardvark Therapeutics reported revenue of $0 million in fiscal 2025. Free cash flow was −$54 million. The diluted share count rose 391.1%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Aardvark Therapeutics does
Aardvark Therapeutics is a clinical-stage drug developer: it has no approved products and no sales yet. It is working on pills meant to reduce hunger in people with metabolic diseases. Its drugs act on bitter taste receptors in the gut, which, when triggered, release the body's own hormones that signal fullness to the brain.
Its lead drug, ARD-101, is being tested for the constant, extreme hunger of Prader-Willi Syndrome, a rare genetic disorder. A second program, ARD-201, combines ARD-101 with an existing diabetes drug and was being tested for keeping weight off after people stop losing weight on GLP-1 drugs. In February 2026 the company paused enrollment and dosing in its late-stage ARD-101 trial and its follow-on study after reversible heart-related findings in a study of healthy volunteers, and it then also paused the two ARD-201 trials while it reviews the data with the FDA.
Aardvark went public in February 2025 and received net proceeds of about $87.5 million from the offering. It had 40 full-time employees in the United States at the end of February 2026.
Its biggest risks, as it describes them
- It has no approved products, has lost money since it began, and needs a lot more funding to keep developing its drugs.
- Its business depends heavily on ARD-101, whose main trial is paused after heart-related findings.
- Trials may show safety problems or fail to show the drugs work, delaying or ending approval.
- Prader-Willi Syndrome is rare, so finding and enrolling enough patients for trials may be hard.
- Larger drug companies may bring rival hunger and obesity treatments to market first or sell them more successfully.
Income statement
Aardvark Therapeutics lost money in fiscal 2025: a net loss of $58 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | 74 | 110 |
| Debt incl. finance leases | — | — |
| Net debt (negative means net cash) | — | — |
| Net debt to EBITDA | — | — |
| Debt to equity | — | — |
| Interest coverage | — | — |
| Current ratio | 15.1x | 10.6x |
| Quick ratio | 15.1x | 10.6x |
Cash flow
Projections
Project Aardvark Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Aardvark Therapeutics says to expect
- Cash runway: existing cash and short-term investments
Based on current operating plans, Aardvark believes that its existing cash, cash equivalents and short-term investments will be sufficient to fund projected operations through 2027.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $144,630 of Aardvark Therapeutics shares on the open market, and 1 insider sold $394,930, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Nelson SunSee Remarks | Sold plan | 62,000 | $5.18 | $321,160 | Form 4 |
| Sep 10, 2026 | Nelson SunSee Remarks | Sold plan | 14,754 | $5.00 | $73,770 | Form 4 |
| Dec 11, 2025 | Tien-Li LeeChief Executive Officer, Director, 10% owner | Bought | 7,000 | $14.49 | $101,430 | Form 4 |
| Dec 11, 2025 | Nelson SunChief Financial Officer | Bought | 3,000 | $14.40 | $43,200 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY25 |
|---|---|
| Piotroski F-score | — |
| Rule of 40 | — |
| Altman Z'' | 9.47 |
| Accruals ratio | −3.5% |
The nine F-score tests
| Test | FY25 |
|---|---|
| Net income is positive | Fail |
| Cash from operations is positive | Fail |
| Return on assets rose | — |
| Cash from operations exceeds net income | Pass |
| Debt fell relative to assets | — |
| Current ratio rose | Fail |
| Share count didn't rise | Fail |
| Gross margin rose | — |
| Revenue rose relative to assets | — |
| F-score | — |
Compare
Put Aardvark Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Aardvark Therapeutics | FY25 | — | — | — | — | — | — | |
| ABVC BioPharma | FY25 | −41.9% | −2,416.0% | — | — | — | — | Compare |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
| Agios Pharmaceuticals | FY25 | 48.0% | −873.9% | −698.3% | — | — | — | Compare |
2 years of figures
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Revenue | — | 0 |
| Revenue growth | — | — |
| Gross profit | — | — |
| Research and development | 17 | 49 |
| Operating income | −23 | −63 |
| Net income | −21 | −58 |
| Diluted EPS (US$) | −5.15 | −2.93 |
| Diluted shares (millions) | 4 | 20 |
| Cash flow | ||
| Cash from operations | −18 | −54 |
| Capital expenditure | 0 | 0 |
| Free cash flow | −18 | −54 |
| Dividends paid | 0 | 0 |
| Share buybacks | 0 | 0 |
| Acquisitions | 0 | 0 |
| Stock-based compensation | 0 | 4 |
| Balance sheet at fiscal year end | ||
| Cash and short-term investments | 74 | 110 |
| Debt incl. finance leases | — | — |
| Total assets | 78 | 117 |
| Total liabilities | 5 | 10 |
| Shareholders' equity | −55 | 107 |
| Margins and ratios | ||
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
| Free cash flow margin | — | — |
| Rule of 40 (growth + FCF margin) | — | — |
| Return on capital | — | — |
| Return on equity | — | −221.6% |
| Return on assets | — | −59.2% |
| Net debt to EBITDA | — | — |